Premium
Activatable Semiconducting Theranostics: Simultaneous Generation and Ratiometric Photoacoustic Imaging of Reactive Oxygen Species In Vivo
Author(s) -
Yang Zhen,
Dai Yunlu,
Yin Chao,
Fan Quli,
Zhang Wansu,
Song Justin,
Yu Guocan,
Tang Wei,
Fan Wenpei,
Yung Bryant C.,
Li Jie,
Li Xiang,
Li Xiangchun,
Tang Yufu,
Huang Wei,
Song Jibin,
Chen Xiaoyuan
Publication year - 2018
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201707509
Subject(s) - materials science , reactive oxygen species , in vivo , nanoprobe , photodynamic therapy , photoacoustic imaging in biomedicine , nanotechnology , nanoparticle , chemistry , biochemistry , organic chemistry , physics , microbiology and biotechnology , optics , biology
Enhancing the generation of reactive oxygen species (ROS) is an effective anticancer strategy. However, it is a great challenge to control the production and to image ROS in vivo, both of which are vital for improving the efficacy and accuracy of cancer therapy. Herein, an activatable semiconducting theranostic nanoparticle (NP) platform is developed that can simultaneously enhance ROS generation while self‐monitoring its levels through ratiometric photoacoustic (PA) imaging. The NP platform can further guide in vivo therapeutic effect in tumors. The theranostic NP platform is composed of: (i) cisplatin prodrug and ferric ion catalyst for ROS generation, a part of combination cancer therapy; and (ii) a ratiometric PA imaging nanoprobe consisting of inert semiconducting perylene‐diimide (PDI) and ROS activatable near‐infrared dye (IR790s), used in ratiometric PA imaging of ROS during cancer treatment. Ratiometric PA signals are measured at two near‐infrared excitation wavelengths: 680 and 790 nm for PDI and IR790s, respectively. The measurements show highly accurate visualization of • OH generation in vivo. This novel ROS responsive organic theranostic NP allows not only synergistic cancer chemotherapy but also real‐time monitoring of the therapeutic effect through ratiometric PA imaging.